Inhalation delivery of topotecan is superior to intravenous exposure for suppressing lung cancer in a preclinical model

Intravenous (IV) topotecan is approved for the treatment of various malignancies including lung cancer but its clinical use is greatly undermined by severe hematopoietic toxicity. We hypothesized that inhalation delivery of topotecan would increase local exposure and efficacy against lung cancer whi...

Descripción completa

Detalles Bibliográficos
Autores principales: Kuehl, Philip J., Grimes, Marcie J., Dubose, Devon, Burke, Michael, Revelli, David A., Gigliotti, Andrew P., Belinsky, Steven A., Tessema, Mathewos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6058531/
https://www.ncbi.nlm.nih.gov/pubmed/29779406
http://dx.doi.org/10.1080/10717544.2018.1469688

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6058531/
https://www.ncbi.nlm.nih.gov/pubmed/29779406
http://dx.doi.org/10.1080/10717544.2018.1469688

Ejemplares similares